0001209191-18-021358.txt : 20180323 0001209191-18-021358.hdr.sgml : 20180323 20180323091759 ACCESSION NUMBER: 0001209191-18-021358 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180322 FILED AS OF DATE: 20180323 DATE AS OF CHANGE: 20180323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cagle Gerald D. CENTRAL INDEX KEY: 0001589991 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37783 FILM NUMBER: 18708524 MAIL ADDRESS: STREET 1: 135 U.S. HIGHWAY 206 STREET 2: SUITE 15 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clearside Biomedical, Inc. CENTRAL INDEX KEY: 0001539029 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452437375 STATE OF INCORPORATION: GA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: 2Q ZIP: 30005 BUSINESS PHONE: 678-270-3631 MAIL ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: 2Q ZIP: 30005 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-22 0 0001539029 Clearside Biomedical, Inc. CLSD 0001589991 Cagle Gerald D. C/O CLEARSIDE BIOMEDICAL, INC. 900 NORTH POINT PARKWAY, SUITE 200 ALPHARETTA GA 30005 1 0 0 0 Common Stock 2018-03-22 4 P 0 7500 11.89 A 23441 D Common Stock 14064 I See Footnote This transaction was executed in multiple trades at prices ranging from $11.83 to $11.95, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Cagle Business Interests, Ltd. is the record holder of these securities. The reporting person is the general partner of Cagle Business Interests, Ltd. and may be deemed to share voting and dispositive power over these securities. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. /s/ Brian F. Leaf, Attorney-in-Fact 2018-03-23